# A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH Patients

> **NCT06712771** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Visirna Therapeutics HK Limited** · enrollment: 46 (actual)

## Conditions studied

- Homozygous Familial Hypercholesterolemia (HoFH)

## Interventions

- **DRUG:** VSA003
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06712771
- **Lead sponsor:** Visirna Therapeutics HK Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-27
- **Primary completion:** 2025-12-31
- **Final completion:** 2027-12-30
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06712771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06712771, "A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06712771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*